Our discussions during this conference call will include forward-looking statements about, among other things, our oncology strategy, our in-line and pipeline oncology portfolio, including Ibrance, avelumab, our immuno-oncology portfolio, and other in-line products and product candidates, including their potential benefits, and our anticipated future operating and financial performance, business plans and prospects, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information regarding these factors can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in our subsequent reports on Form 8-K, all of which are filed with the SEC and available at www.sec.gov and www.pfizer.com. The forward-looking statements in this presentation speak only as of the original date of this presentation and we undertake no obligation to update or revise any of these statements.
To be a Leader in Oncology by Speeding Cures and Accessible Breakthrough Medicines to Patients, Redefining Life with Cancer

Leadership
A serious commitment to being leaders in Oncology

Accessible
Establish the value of these medicines so patients everywhere can access them

Speed
Bring these medicines to patients as quickly and safely as possible

Cures or Breakthrough
Seek medicines that provide meaningful, not marginal, impact that restore patient life – without compromising quality of that life

Redefining Life with Cancer
Be a partner to patients-be the company that redefines life with cancer
Focused To Achieve Our Goals

To be a Leader in Oncology by **Speeding Cures and Accessible Breakthrough Medicines to Patients, Redefining Life with Cancer**

**Key Focus Areas**

- **Ibrance**
  - Partner with and support key stakeholders in the breast cancer community
  - Generate data/evidence for optimal use of Ibrance

- **Immunology**
  - Avelumab: backbone PD-L1 therapy
  - Identify and interrogate rational combinations
  - 10 potential compounds in 2016

- **Create a “Breakthrough” Pipeline**
  - Agile Discovery and Development Engine to Speed Breakthrough Therapies to Patients

**Partnerships & Collaborations**
Beyond Monotherapy PD/ PD-L1, Significant Untapped Need Remains for the Vast Majority

Response Rates Can Vary by Molecule and Tumor Type

"Bridging the Gap" Requires

• Commitment to transformational break-through clinical impact for patients through rational combinations

• Focused expertise in our existing assets/molecules and the indications in which they are most promising

• Leveraging partnerships to learn faster

We are Aiming to be Amongst the Leaders Bringing Rational Combinations to Patients

Source: Analyst Reports, clinicaltrials.gov, SEER
Key Data at ASCO 2016
Pfizer Oncology’s Biggest ASCO Yet

50 Abstracts Accepted Across 15 Tumor Types

Highlights

- **Palbociclib**: Phase III PALOMA-2 trial demonstrated impact of adding palbociclib to letrozole as 1L therapy for women with ER+/HER2- advanced BC

- **Utomilumab + Pembrolizumab**: Phase Ib trial demonstrated immune activation, clinical efficacy and attractive safety profile in patients with advanced solid tumors

- **Avelumab**: Phase II trial demonstrated clinically significant response rate and duration of response in patients with previously treated Merkel Cell Carcinoma

- **Lorlatinib**: Phase I trial assessed safety and efficacy in patients with advanced ALK+ or ROS1+ NSCLC

- **Crizotinib**: Phase II trial highlighting efficacy and safety of crizotinib in patients with advanced cMET Exon 14-altered NSCLC

- **Palbociclib**: Subset analysis from PALOMA-3 showed efficacy of palbociclib plus fulvestrant in patients with mBC and ESR1 mutations in circulating tumor DNA
Key Data at ASCO 2016: Combination Immuno-Oncology Pembrolizumab + Utomilumab: Evidence of Immune Response

Lymphocyte Subsets Observed at Cycle 5 Day 1

- Strong pre-clinical rationale for targeting both PD-1 + 4-1BB
- Patients with clinical response had an increase in total lymphocytes, activated and effector/memory CD8+ T cells

Presented at ASCO by: Anthony W. Tolcher, MD, FACP
Key Data at ASCO 2016: Combination Immuno-Oncology
Pembrolizumab + Utomilumab: Evidence of **Clinical Activity**

Waterfall Plot: Maximum Tumor Shrinkage

Abstract 3002
Phase 1b study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Anthony W. Tolcher, MD, FACP
South Texas Accelerated Research Therapeutics (START) San Antonio
Key Data at ASCO 2016: Avelumab: Efficacy in Merkel Cell Carcinoma (previously treated)

Patients with Baseline and at Least One Post-baseline Target Lesion Assessment (n=65)

Abstract 9508
Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic Merkel cell carcinoma previously treated with chemotherapy:
Results of the Phase 2 JAVELIN Merkel 200 trial
Presenter: Howard Kaufman, MD
Rutgers Cancer Institute of New Jersey
Significant Oncology Pipeline Opportunities in the Next Five Years

**In-Line**

- ibecephem
- axitinib
- xalkori
- rapiwed
- bosulif
- sutent
- ibrance

**Near-term**

- inotuzumab ozogamicin (lead indication)
- avelumab
- mylotarg
- dacomitinib

**Medium-term**

- lorlatinib
- 4-1BB
- glasdegib
- avelumab (several indications)

**Timeframes**

- Today
- 1-2 Years
- 2-5 Years